Moreserc

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Moreserc

What is Moreserc? (Composition: Betahistine)

Property Description
Active ingredient Betahistine dihydrochloride
Form Oral tablet
Pharmacological class Histamine analogue, Anti-vertigo agent
Common use Mitigating symptoms of vertigo
Origin Synthetic compound

What Type of Medicine is Moreserc?

Moreserc is a prescription-only medicine (Rx) primarily classified as an antivertigo agent, designed to help relieve symptoms arising from disturbances within the inner ear. The drug is a synthetic compound supplied as an oral formulation (a tablet) intended for systemic delivery. It is pharmacologically designated as a histamine analogue, a classification that sets it apart from general anti-motion sickness drugs by indicating a more specific mechanism of action aimed at the vestibular system. This classification corresponds to the anatomical therapeutic chemical classification system for antivertigo preparations.


What is Betahistine, the Active Ingredient?

The sole active ingredient in Moreserc is Betahistine, formulated as Betahistine dihydrochloride, making the product a single-ingredient monotherapy. This substance is responsible for the drug’s distinct therapeutic effect. Betahistine acts on both H1 and H3 histamine receptors, which is believed to influence inner ear function and neurotransmitter signaling. Betahistine is associated with improving microcirculation within the inner ear, which is vital for the proper function of the balance organs.


What is the General Purpose of Moreserc?

The general purpose of Moreserc is to help mitigate the intensity and recurrence of vestibular symptoms, notably the sensation of spinning known as vertigo. The drug's therapeutic goal is achieved through its action as a peripheral vasodilator, enhancing inner ear circulation, and its ability to regulate nerve signals. This targeted approach aims to support the stabilization of the patient's balance system, providing relief from chronic dizziness linked to inner ear disturbances. The common use scenario involves managing recurring episodes of intense dizziness or imbalance associated with inner ear dysfunction.

What side effects are possible with Moreserc?

Possible Side Effects and Safety Information

The safety characteristics of Moreserc, which contains Betahistine, are documented in official regulatory materials, using a standardized classification system for adverse reactions based on frequency and the body system affected.

Documented Frequencies and Organ Systems

Adverse reactions are classified by the System-Organ Class (SOC) affected. The following are reported in official labeling:

Classification Organ System Affected Reported Adverse Reactions
Common Nervous System Disorders Headache, occasional drowsiness
Common Gastrointestinal Disorders Nausea, dyspepsia (indigestion)
Not Known Immune System Disorders Hypersensitivity reactions (e.g., anaphylaxis)
Not Known Skin and Subcutaneous Tissue Disorders Angioneurotic oedema, urticaria, rash, pruritus

Reactions with Common frequency affect 1 to 10 users in every 100. Reactions categorized as Not Known are derived from post-marketing reports and their true incidence cannot be reliably estimated from available data.

Serious Adverse Reactions and Key Safety Constraints

Serious adverse reactions officially listed, although classified as Not Known frequency, include severe forms of hypersensitivity such as anaphylaxis and angioneurotic oedema (rapid tissue swelling).

Safety Restrictions define when the medicine must not be used or requires particular caution:

  • Contraindications: Moreserc is strictly contraindicated in individuals with phaeochromocytoma and in those with known hypersensitivity to the active substance.
  • Cautionary Use: Official labeling advises caution for patients with a history of peptic ulceration or bronchial asthma.

Regarding specific patient groups, use in the pediatric population (under 18 years) is not recommended due to insufficient safety and efficacy data in this age group, as documented in regulatory texts.

Overdose and Emergency Response

The official regulatory profile for Moreserc (Betahistine) overdose distinguishes between expected presentations and severe outcomes, strictly focusing on mandated emergency actions.

Documented Overdose Manifestations

Overdose may present with a cluster of signs, including nausea, vomiting, abdominal pain, dyspepsia, somnolence (drowsiness), and ataxia (coordination problems). More serious, life-threatening complications have been observed, specifically convulsions (seizures), cardiac complications, and pulmonary complications. These severe outcomes are primarily documented in cases of intentional ingestion of high doses or in combination with other overdosed substances.

When to Seek Immediate Medical Help

Regulatory labeling universally states that immediate medical attention is required in all suspected cases of overdose. Contacting a poison control center or the nearest hospital emergency department is the mandated action, even if the individual appears to be without symptoms.

Since no specific antidote is known for Betahistine, management is limited to standard supportive measures and symptomatic treatment. Officially described procedural steps may include gastric lavage if administered within one hour of ingestion, as detailed in prescribing information. This approach structures the official emergency response to overdose risk.

Therapeutic Uses of Moreserc

What Moreserc Treats: Main Uses and Benefits

The active ingredient in Moreserc is commonly used for managing the challenging symptoms associated with conditions characterized by periods of heightened symptoms, specifically those relating to inner ear disorders. Moreserc is utilized in therapeutic domains involving certain distressing symptoms like severe, episodic vertigo, bothersome tinnitus (ringing in the ears), and fluctuating hearing loss.

The medication is relevant for easing this challenging cluster of symptoms that often creates noticeable functional strain. It is often used when symptoms intensify, and supportive relief is needed to address the intense spinning sensations and the accompanying nausea and vomiting. This provides support that helps ease the overall symptom burden.

“Moreserc is relevant for easing symptom clusters that may become intense or disruptive and contributes to improved comfort during symptomatic periods.”

Quick Fact: Symptomatic Focus

Moreserc is primarily used to help manage the intensity and frequency of severe, episodic vertigo attacks, which supports the maintenance of functional stability when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Who Can and Cannot Use Moreserc? — Official Regulatory Information

This section outlines the population eligibility and non-eligibility rules for Moreserc (Betahistine) based strictly on authoritative governmental regulatory documents.


Eligibility Scope

Category Status/Rule
Populations for whom use is allowed Adults (18 years and over); older adults (no dose adjustment typically needed).
Populations for whom use is not recommended Children and adolescents under 18; pregnant women; breastfeeding women.
Populations for whom use is contraindicated Individuals with known hypersensitivity to the drug; patients with pheochromocytoma (adrenal tumor).

Eligibility Classifications (Key Constraints)

  • Age-Related Rule: Use is not recommended for patients below 18 years due to insufficient data on safety and efficacy in this group.
  • Condition-Specific Rule: Use requires caution and careful monitoring for individuals with bronchial asthma or a history of peptic ulcer. Caution is also advised for patients with severe hypotension.
  • Reproductive Status: The medicine should not be used during pregnancy unless clearly necessary, and is not recommended during lactation.

Connection to the Overall Eligibility Profile

The official profile is governed by absolute prohibitions for specific conditions like pheochromocytoma and drug allergy. Furthermore, use is formally defined as not recommended for the pediatric population and during pregnancy and lactation due to data limitations. Conditional use is required for patients with certain comorbidities, such as asthma or peptic ulcer disease, which necessitate careful monitoring under the medicine's approved labeling.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The interaction profile for Moreserc (Betahistine) is documented in official regulatory sources, outlining specific pharmacokinetic and pharmacodynamic constraints. These statements focus strictly on how co-administered substances officially alter the medicine's activity or concentration.


Medicinal Product Interactions

Interacting Substance/Class Official Interaction Statement (Constraint)
Monoamine-oxidase Inhibitors (MAOIs) Co-administration may result in an increase in the exposure (plasma levels) of Betahistine. This includes MAO subtype B selective inhibitors like Selegiline.
Antihistamines (H1 Antagonists) Official documents note the theoretical risk of a mutual attenuation of effect. Co-administration is generally advised against due to this pharmacodynamic constraint.
Metabolic Enzymes (CYP) Moreserc is not expected to cause clinically relevant inhibition of Cytochrome P450 (CYP) enzymes, based on in vitro data.

Interactions with Food and Substances

Substance Official Interaction Statement (Outcome)
Food Intake Taking Moreserc with food slows the rate of absorption; however, this effect does not modify the overall amount of the medicine (bioavailability) absorbed into the body.
Ethanol (Alcohol) Regulatory records include documentation of a case report concerning an interaction involving ethanol.

Interaction Summary: The regulatory profile defines the product's interaction structure primarily through metabolic interference with MAO inhibitors and pharmacodynamic antagonism with H1 antagonists. No mandatory timing rules for dose separation are documented in official regulatory sources.

Mechanism of Action

The physiological effects of Moreserc, a synthetic analogue, stem from its dual action on the histamine system, simultaneously engaging both central and peripheral pathways to modulate equilibrium pathways. The drug functions as an antagonist (blocker) at presynaptic histamine H3 receptors ( H3 R) within the brainstem's vestibular nuclei. This action removes a natural inhibitory constraint, thereby increasing the release of the body’s own histamine and other key neurotransmitters. The resulting enhanced central neural activity facilitates vestibular compensation, the functional process of re-calibrating unequal signals to support the functional re-calibration of input signals. A second, complementary mechanism involves Moreserc's action as a partial agonist at histamine H1 receptors ( H1 R) on the smooth muscles of the inner ear's blood vessels. This receptor engagement promotes localized vasodilation, leading to increased blood flow to the cochlea and vestibular apparatus. This peripheral vascular action facilitates the regulation of fluid pressure (endolymph) within the balance organs, which influences the sensory input signals sent to the brain. The combined central H3 antagonism and peripheral H1 agonism results in the modulation of the physiological state of equilibrium pathways.

Dosage and Administration Information

How to Use Moreserc

Moreserc (Betahistine) is a prescription medicine delivered exclusively via the oral route as a tablet. Usage is structured to support consistent administration and adherence to specific dosing ranges.

Administration Guidelines

Usage Principle Administration Details
Route of Administration Moreserc is supplied as an oral tablet for systemic delivery.
Standard Adult Dose The standard total daily dose ranges from 24 mg to 48 mg (maximum daily dose), taken in divided amounts.
Dosing Frequency The total daily dose must be administered in divided doses—typically two or three times—throughout the day.
Timing in Relation to Meals Tablets should be taken with food or immediately after meals. This is a common instruction to help support administration.
Treatment Duration Treatment is often implemented as a long-term plan spanning several months, as optimal effects may not be observed immediately.
Tablet Preparation Tablets are swallowed with water. Some larger tablets (e.g., 24 mg) are scored and can be divided into equal halves for easier intake or flexibility in administering the total daily dose.

Population-Specific Use

No specific dose adjustment is required for older adults or for patients presenting with renal or hepatic impairment. However, use of Moreserc is not recommended for the pediatric population (individuals under 18 years of age) due to insufficient established data regarding its safety and efficacy in this group.

The procedural structure of taking the tablet in a divided-dose schedule, with food, characterizes the method of using this medicine for its intended purpose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Moreserc

Moreserc, which contains the active ingredient Betahistine, has been the subject of research for several decades, primarily in adult populations with dizziness and spinning sensations (vertigo) linked to inner ear disturbances. The body of evidence includes rigorous Randomized Controlled Trials (RCTs) and scientific Systematic Reviews that research examined how the active ingredient, Betahistine, was observed in patients with conditions characterized by fluctuating or episodic manifestations. The evidence is typically examined by looking at what was measured in the studies and how the reported patterns compare to a placebo or no treatment.


Evidence for Use in Ménière's Syndrome/Disease

Research related to Betahistine in the context of Ménière's syndrome/disease was studied for outcomes describing episodic or acute changes. One major, long-term RCT involving hundreds of participants explored whether Betahistine was associated with a difference in the number of attacks compared to a placebo over nine months. The study reported that the measured frequency of vertigo attacks observed in the group receiving Betahistine was similar to the frequency observed in the group receiving placebo over nine months. Findings from this trial contribute to the understanding that current evidence is limited concerning the question of whether Betahistine is associated with a lower occurrence of vertigo attacks in Ménière's disease.

Comprehensive scientific reviews indicate that the available evidence is insufficient to characterize patterns of change in associated symptoms like tinnitus or hearing loss. The overall certainty of evidence regarding the question of whether Betahistine is associated with a lower occurrence of vertigo attacks in this population remains low due to mixed findings and methodological challenges in earlier trials.


Evidence for Use in Peripheral Vestibular Vertigo

In research involving broader populations with peripheral vertigo, studies explored short-term symptom changes using smaller trials and data gathered in routine clinical settings. These studies examined outcomes reflecting daily functioning or activity level and utilized scales where patients rated the intensity and variability of their spinning sensation. Reported measurements, including those from observational settings, described shifts in patient-rated severity during the study period. However, the evidence quality varies across studies and many of the trials involved modest sample sizes and only assessed short-term outcomes.

Frequently Asked Questions (FAQ)

Common questions about Moreserc (FAQ)


Q: Does Moreserc start working immediately, or does it take time?

A: According to official product information, the medicine is described as taking some time to begin showing an effect.

In some cases, initial signs of improvement may not become apparent until after the first two weeks of starting the treatment plan.


Q: What is the expected timeline for Moreserc's full effect?

A: Official regulatory guidance indicates that the best results from this treatment are often achieved after several months of consistent and continuous use.

This is because the treatment is usually implemented as a long-term strategy for managing symptoms.


Q: Can Moreserc affect my ability to drive or operate machinery?

A: Regulatory documents state that the medicine itself is not likely to affect a person's ability to drive or use tools or machinery.

However, it is important to be aware that the underlying condition being treated, such as dizziness or nausea, may cause symptoms that could still impact these abilities.


Q: Will Moreserc still work if I miss a dose?

A: Regulatory instructions advise that if a dose is missed, the recommended course is to skip that dose and take the next one at the usual scheduled time.

Patients are advised not to take a double dose of the medicine to compensate for the forgotten amount.


Q: What happens if I take Moreserc for a long period?

A: Treatment with Moreserc is frequently implemented as a long-term plan, often spanning several months or years.

Official regulatory safety documents focus on classifying known common and serious adverse reactions; they do not identify long-term risks that are separate from the established safety profile.


Q: Are there any documented cases of Moreserc overdose symptoms?

A: Official regulatory documents contain information on documented symptoms observed in cases of overdose, which may include feeling sick (nauseous), sleepiness, or stomach pain.

In cases involving very high amounts of the medicine, more serious effects, such as seizures, have been reported.


Q: Can Moreserc be crushed or split if swallowing is difficult?

A: Official guidelines describe that the tablets should be swallowed whole with water. Some larger tablet strengths are manufactured with a score line, which allows them to be divided into equal halves.

However, regulatory documents do not provide official instruction or guidance regarding crushing or dispersing the tablets.


Q: How quickly do the side effects of Moreserc usually go away?

A: Official safety materials provide general information on the duration of common adverse reactions.

For instance, common gastrointestinal side effects, like nausea or indigestion, are noted as usually not serious and may subside between doses of the medicine.


Q: What kind of monitoring is needed while taking Moreserc?

A: Official regulatory labeling advises that individuals with a history of peptic ulceration or those who have bronchial asthma require caution and careful monitoring while using Moreserc.

This monitoring focuses on the status of those pre-existing conditions during treatment.


Q: What is the typical duration of treatment with Moreserc?

A: Treatment is typically established as a long-term plan, often lasting for several months or, in some cases, years.

This extended duration is described because achieving the medicine’s optimal effect may require an extended period of consistent use.


Q: Does Moreserc affect kidney function?

A: Official regulatory documents state that no specific adjustment to the dose is typically required for patients who have renal (kidney) impairment.

This information suggests the medicine is not expected to significantly impact kidney function in the general population.


Q: Does Moreserc contain any common allergens like gluten or lactose?

A: Official product labeling lists all inactive ingredients (excipients).

Some specific formulations of Moreserc tablets are known to contain lactose. Conversely, official documents generally confirm that the product does not contain gluten.


Q: How is Moreserc eliminated from the body?

A: Pharmacokinetic data shows that once absorbed, the active ingredient is rapidly and almost completely converted into a substance called 2-pyridylacetic acid.

This inactive substance is then readily eliminated from the body, primarily through the urine.


Q: How long does Moreserc stay in your system after you stop taking it?

A: Official pharmacokinetic data suggests that the medicine is rapidly processed by the body.

The mean plasma elimination half-life is between 3 to 4 hours, and the substance is considered virtually completely eliminated from the body within 24 hours.


Q: Is Moreserc a new or established medication?

A: The active ingredient contained in Moreserc is considered an established medication.

It was first registered in Europe in the 1970s and has been used in adult populations globally for several decades since that time.


Q: What is the typical age range for people who take Moreserc?

A: Regulatory documents define the allowed population for this medicine as adults, meaning individuals 18 years of age and over, including older adults.

Use is formally not recommended for the pediatric population (individuals under 18 years of age) due to a lack of established safety data.


Q: Is Moreserc known to cause dizziness or lightheadedness?

A: While the medicine is intended to help relieve symptoms of spinning sensations, official safety information mentions that lightheadedness has been reported in some individuals.

Caution is advised for those who have pre-existing low blood pressure (hypotension).


Q: Are there official patient education materials for Moreserc?

A: Yes, authoritative sources provide official patient information materials regarding this medicine.

These materials include the Patient Information Leaflet (PIL) and the Summary of Product Characteristics (SmPC), which contain detailed, regulated information for patient education.


Q: What distinguishes Moreserc from other non-prescription options?

A: Moreserc is classified as a prescription-only medicine and is pharmacologically defined as a histamine analogue.

This classification indicates a mechanism of action specifically targeted at the vestibular system, which differentiates it from general non-prescription remedies used for temporary motion sickness or dizziness.


Q: What evidence supports the use of Moreserc for its intended purpose?

A: The body of evidence supporting the use of the medicine includes rigorous Randomized Controlled Trials and scientific Systematic Reviews.

This research primarily involved adults with symptoms of dizziness and spinning sensations. Studies have examined patient-rated outcomes reflecting the intensity and frequency of these symptoms.


Q: What kind of drug is Moreserc (Synthetic analogue, H1/H3 agonist/antagonist)?

A: Moreserc is classified as a histamine analogue and is primarily designated as an anti-vertigo agent.

Its effect involves a dual action on the histamine system, where it is described as functioning as both an antagonist (blocker) at H3 receptors and a partial agonist at H1 receptors.


Q: What are the expected side effects of Moreserc reported by patients?

A: The most frequently reported adverse reactions are classified as Common, meaning they are reported to affect 1 to 10 users in every 100.

These common reactions are listed as headache, occasional drowsiness, nausea, and dyspepsia (indigestion).


Q: Is it normal to have a slight headache when I first start taking Moreserc?

A: Headache is officially listed in regulatory documents as a Common adverse reaction.

This classification indicates that the symptom is reported by a significant number of individuals (1 to 10 users in every 100) who take the medicine.


Q: Is Moreserc used for things other than the main condition listed?

A: The medicine is authorized by regulatory bodies for its primary purpose of helping to relieve the symptoms associated with inner ear disturbances.

Regulatory documents do not list any other officially approved uses or indications beyond this primary purpose.


Q: How does Moreserc compare generally to other drugs for the same condition?

A: Official regulatory materials describe the medicine's interaction profile rather than providing comparisons to other drugs for the same condition.

The only specific constraint noted involves the theoretical risk of a mutual decrease in effect when Moreserc is taken alongside H1 Antihistamines.


Q: Can Moreserc be taken on an empty stomach?

A: Regulatory guidance advises taking the medicine with food or immediately following meals. This administration method may help to reduce the chance of experiencing mild stomach discomfort.

Pharmacokinetic studies show that while food slows the rate of absorption, it does not change the total amount of medicine absorbed by the body.


Q: What happens if Moreserc is taken with a high-fat meal?

A: Official regulatory documentation addresses the impact of food intake generally.

It states that taking the medicine with food, regardless of type, slows the rate at which the active substance is absorbed but does not modify the overall amount (bioavailability) that enters the body.


Q: Does Moreserc affect blood pressure or heart rate?

A: Official safety information advises caution for individuals with pre-existing low blood pressure (hypotension).

While not typically a common side effect, regulatory documents have reported low blood pressure and an accelerated heartbeat as potential effects observed in cases of overdose.

How should Moreserc be stored and disposed of?

How to Store and Dispose of Moreserc

Official regulatory guidelines strictly define the conditions necessary for storing Moreserc (betahistine dihydrochloride) tablets to maintain product stability and integrity.

Storage Requirements

Moreserc must be stored at temperatures below 25 C. To protect the product from moisture, it is mandatory to keep the medicine in its original container or package. As with all medicines, it is officially required to store Moreserc out of the sight and reach of children.

Disposal Instructions

There are no special requirements for handling Moreserc other than standard protocols for discarding medicines. Any expired or unused tablets, or associated waste material, must be disposed of in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Moreserc found in:

A-Z Index: